On August 29, 2018 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that Scott Wolchko, President and Chief Executive Officer, will present at two upcoming investor conferences in September (Press release, Fate Therapeutics, AUG 29, 2018, View Source [SID1234529135]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Wells Fargo Healthcare Conference at 3:00 p.m. ET on Wednesday, September 5, 2018 in Boston.

Morgan Stanley 16th Annual Global Healthcare Conference at 5:15 p.m. ET on Thursday, September 13, 2018 in New York City.

Live webcasts of the presentation will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company’s website.

On August 29, 2018 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City (Press release, Ligand, AUG 29, 2018, View Source [SID1234529134]). Presentation takes place on Wednesday, September 5, 2018 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). John Higgins, CEO, and Matt Korenberg, CFO, will attend for Ligand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on Ligand’s website at www.ligand.com. A replay of the presentation will be archived on the website for 30 days.

On August 29, 2018 Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reported that company management will present at the following investor conferences in September (Press release, Cambrex, AUG 29, 2018, View Source [SID1234529133]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Wells Fargo Healthcare Conference
Date: Wednesday, September 5, 2018
Time: 3:00 p.m. EDT
Location: Boston, MA

Morgan Stanley 16th Annual Global Healthcare Conference
Date: Friday, September 14, 2018
Time: 9:55 a.m. EDT
Location: New York, NY

The live audio webcast and slide presentations can be accessed from the Cambrex website at www.cambrex.com in the Investors section under "Webcasts & Presentations", and replays will be available for 90 days after the live events conclude.

On August 29, 2018 Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported that the company’s management team will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, Sept. 5, at 3:00 p.m. EDT (Press release, Endocyte, AUG 29, 2018, View Source [SID1234529132]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Company’s presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

Website Information

Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the "Investors & News" section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the "Investors & News" section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.

On August 29, 2018 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that company management will present at two investor conferences in September (Press release, Iovance Biotherapeutics, AUG 29, 2018, View Source [SID1234529131]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 H.C. Wainwright Annual Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at 10:50 a.m. ET

Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m. ET
A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics’ website at View Source A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.